Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies.

Jinhui XueHaipeng HeZuan LinYuehan WuYuehao LinHongyun ZhaoSalvatore J SalamoneYan HuangYunpeng YangWenfeng FangYang ZhangShaodong HongYuxiang MaYuxiang Ma

Published in: Cancer chemotherapy and pharmacology (2022)

Patients with PTX Tc > 0.05 duration above 39 h experience more severe neutropenia than those under 39 h. Prospective studies are needed to verify this threshold.

Keyphrases

phase ii
end stage renal disease
clinical trial
ejection fraction
chronic kidney disease
newly diagnosed
chemotherapy induced
prognostic factors
peritoneal dialysis
case control
oxidative stress
randomized controlled trial
double blind
patient reported